A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults with Elevated Lp(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event (ACCLAIM-CTA)

Principal Investigator

Rafail Kotronias

Contact us

Email: cvm_nurses@cardiov.ox.ac.uk

IRAS number

1014051